BIOR241220C2000
- 0.00
- 0.000.00%
Biora Therapeutics Newsroom
HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Adjusts Price Target To $23 (1-10 Reverse Stock Split)
Biora Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Analyst Ratings
Biora Therapeutics Buy Rating Confirmed by Positive Phase 1 Trial Outcomes and NaviCap Technology Potential
HC Wainwright & Co. : Biora Therapeutics (BIOR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.
Biora Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
Analysts' Top Healthcare Picks: Biora Therapeutics (BIOR), Irhythm Technologies (IRTC)
BTIG Keeps Their Buy Rating on Biora Therapeutics (BIOR)
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $50 Price Target
Biora Therapeutics Analyst Ratings
Biora Therapeutics (BIOR) Receives a Buy From BTIG
Analysts Offer Insights on Healthcare Companies: Biora Therapeutics (BIOR), Bolt Biotherapeutics (BOLT) and Immunovant (IMVT)
HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50
Biora Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Omega Therapeutics (OMGA) and Biora Therapeutics (BIOR)
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $65 Price Target
Biora Therapeutics Analyst Ratings